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1. Introduction
The frequency of adrenal incidentalomas has been reported to range between 0.7% and 4%
in abdominal computed tomography [1-5], or from 1.4% to 8.7% in autopsy series [6-8]. The
widespread application of high resolution imaging techniques, such as computed tomogra‐
phy, magnetic resonance imaging and ultrasonography, has led to an increasing frequency
of discovering adrenal incidentalomas. The majority of these lesions are of cortical origin, in‐
clude non-functioning adenomas, adenomas associated with pre-clinical Cushing's syn‐
drome, pheochromocytomas, adrenocortical carcinomas, myelolipomas, ganglioneuromas,
metastatic tumors and cysts [9-13]. Adrenal incidentalomas are usually asymptomatic, how‐
ever many of these lesions may secrete weak precursor hormones or active hormones in in‐
sufficient amounts to cause clinically apparent disease. There are reports of several cases of
adrenal incidentaloma who had no clinical evidence of Cushing’s syndrome and normal
basal steroid hormone secretion, but non-suppressible serum cortisol after dexamethasone
administration. These cases were regarded as “pre-clinical Cushing’s syndrome” [14-16] and
many of them treated by adrenalectomy, which restored a normal cortisol suppression to
dexamethasone.
To study the differences between non-functioning adenomas and those associated with pre-
clinical Cushing's syndrome, we performed a comprehensive analysis of serum steroid hor‐
mone profiles in patients with such adrenocortical tumors using a combination method of
high-performance liquid chromatography(HPLC) and radioimmunoassay(RIA) [17].
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2. Materials and Methods
2.1. Subjects
We studied 22 patients with incidentally discovered adrenal masses. These lesions were
seen on abdominal imaging and were diagnosed clinically and/or pathologically. From our
adrenal incidentaloma cases, we selected for inclusion only patients with adrenocortical ade‐
nomas. Fifteen non-functioning adenoma cases (7 males and 8 females, mean age 59.3±13.7
yr) and seven pre-clinical Cushing's syndrome cases (2 males and 5 females, mean age
54.7±12.4 yr) were studied (Table 1). As the control group, sixteen healthy adults(8 males
and 8 females, mean age 51.0±7.4 yr) were used.
Non-functioning No Age(yr) Sex Side Size(mm) BP(mmHg) Operation
1 71 M right 25x15 150-80 (+)
2 83 M right 30x20 160-84
3 74 M right 30x20 146-86 (+)
4 61 M left 8x8 130-70
5 49 M right 22x13 134-78
6 42 M left 18x12 138-80
7 53 M left 19x17 142-82
8 87 F right 32x15 100-80
9 57 F left 12x12 140-80
10 53 F right 22x18 104-60 (+)
11 55 F right 12x9 120-76
12 49 F right 26x19 124-80 (+)
13 42 F left 21x18 144-84
14 56 F left 32x21 128-72 (+)
15 57 F left 25x29 146-84
Pre-clinical 1 41 M left 15x10 146-88
Cushing 2 54 M left 16x11 148-84
3 61 F right 18x18 130-84 (+)
4 60 F right 17x13 160-70 (+)
5 59 F right 17x15 130-82
6 72 F right 18x12 156-86 (+)
7 36 F left 22x18 124-80 (+)
Table 1. Clinical features in cases of non-functioning adenoma and pre-clinical Cushing’s syndrome
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2.2. Hormonal measurements
Blood samples were obtained from patients with adrenal masses and normal subjects be‐
tween 8 and 9 a.m. after an overnight fast. Serum levels of 10 steroid hormones ［pregneno‐
lone (Preg), progesterone (P), deoxycorticosterone (DOC), corticosterone (B), 17-
hydroxypregnenolone (17-OH-Preg), 17-hydroxyprogesterone (17-OHP), 11-deoxycortisol
(S), cortisol (F), dehydroepiandrosterone (DHEA), △4androstenedione (△4A)］ were deter‐
mined by an HPLC/RIA method as previously described [17].
 
2.3. Statistical analyses
We analyzed product/precursor ratios as indices of the relative activities of adrenal ster‐
oidogenic enzymes. Data are shown as mean ± SD. Variables were compared by the Mann-
Whitney  U  test  with  Bonferroni  correction.  P  values  less  than  0.05  were  considered
statistically significant.
 
2.4. Results
Eleven cases of non-functioning adenomas (Group I) had normal levels in DHEA and △4A
compared to normal controls by simultaneous analysis (Fig.1).In 4 cases of non-functioning
adenomas (Group II), however, serum levels of DHEA and △4A were significantly de‐
creased compared to normal controls by simultaneous analysis (Fig.2). Other steroid hor‐
mone levels were normal in all cases of non-functioning adenomas. Therefore, we divided
these patients into two groups based on the relative activities of adrenal steroidogenic en‐
zymes by calculating product/precursor ratios. In pre-clinical Cushing's syndrome, serum
levels of DHEA and △4A were significantly decreased compared to normal control values
(Fig.3) and these results were similar to values in Group II patients.
17,20-Lyase activities assessed by DHEA/17-OH-Preg and △4A/17-OHP ratios were signif‐
icantly decreased in Group II of non-functioning adenoma and pre-clinical Cushing's syn‐
drome compared to Group I patients and normal controls (Fig.4). 17-Hydroxylase activities
assessed by 17-OH-Preg/Preg and 17-OHP/P ratios (Fig.5), 3β-hydroxysteroid dehydrogen‐
ase activities assessed by P/Preg, 17-OHP/17-OH-Preg and △4A/DHEA ratios (Fig.6),  21-
hydroxylase  activities  assessed  by  DOC/P  and  S/17-OHP  ratios  (Fig.7)  and  11β-
hydroxylase activities assessed by B/DOC and F/S ratios (Fig.8) had the same levels in all
cases of non-functioning adenomas and pre-clinical Cushing's syndrome compared to nor‐
mal control values.
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Figure 1. Serum steroid hormone profiles in non-functioning adrenocortical adenoma Group I
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Figure 2. Serum steroid hormone profiles in non-functioning adrenocortical adenoma Group II
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Figure 3. Serum steroid hormone profiles in pre-clinical Cushing's syndrome
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Figure 4. 17,20-Lyase activities
Figure 5. 17-Hydroxylase activities
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Figure 6. 3β - Hydroxysteroid dehydrogenase activities
Figure 7. 21- Hydroxylase activities
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Figure 8. 11β -Hydroxylase activities
3. Discussion
We examined serum steroid hormone profiles of patients with non-functioning adrenocorti‐
cal adenomas and pre-clinical Cushing's syndrome. We also assessed the steroidogenic en‐
zymatic activities of these patients by analysis of the product/precursor ratios of C21 and
C19 steroid hormones in the steroidogenic pathway. Patients with pre-clinical Cushing's
syndrome and a subgroup of patients with non-functioning adrenocortical adenomas had
distinctly decreased adrenal androgen secretion compared with a suppressed 17,20-lyase ac‐
tivity. The remaining patients with non-functioning adrenocortical adenomas had complete‐
ly normal adrenal androgen values and 17,20-lyase activity.
Previous reports have shown an exaggerated response of 17-hydroxyprogesterone after
ACTH stimulation in some patients with incidentally detected adrenal incidentalomas
[18,19]. This response has been explained by existing 21-hydroxylase deficiency which may
be a pathogenetic factor in the development of adrenal tumors. Macronodular adrenal hy‐
perplasia is a frequent finding in patients with classic congenital adrenal hyperplasia, how‐
ever,also about half of the heterozygous carriers in families with congenital adrenal
hyperplasia were reported to have uni- or bilateral adrenal nodules on abdominal computed
tomography in consecutive 4-mm scans [19].These investigators concluded that mild 21-hy‐
droxylase deficiency is associated with the formation of adrenal incidentaloma. Other inves‐
tigators have reported that the ACTH-stimulated 17-hydroxyprogesterone levels were
abnormally increased in more than 50% of patients with non-hyperfunctioning adrenal ade‐
nomas [20]. After unilateral adrenalectomy, this hormonal abnormality disappeared in most
patients with adrenal tumors. The ACTH-stimulated 17-hydroxyprogesterone levels signifi‐
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cantly correlated with the size of the tumors. These results indicate that tumors themselves
may be responsible for the increased ACTH-stimulated 17-hydroxyprogesterone levels in
patients with non-hyperfunctioning adrenal adenomas.
In this study, we demonstrated that serum DHEA and △4A levels were significantly de‐
creased in some patients with non-functioning adrenocortical adenomas(Group II) and all
those with pre-clinical Cushing's syndrome. 17,20-Lyase activities were significantly de‐
creased in Group II of non-functioning adenoma and pre-clinical Cushing's syndrome com‐
pared to Group I patients and normal controls. We found no clinical or pathological
differences between Group I patients and Group II patients who had normal adrenal andro‐
gen concentrations. We have no explanation as to why there was difference between these
groups. Since serum steroid hormone profiles had a similar pattern between some non-func‐
tioning adrenocortical adenomas and adenomas of patients with pre-clinical Cushing's syn‐
drome, we suggest that the former may in time progress into pre-clinical and clinical
Cushing's syndrome. There are limitations in this study such as small sample size and no
tissue investigation. In the future the activity of steroidogenesis enzyme should be meas‐
ured in the specimens from adrenaltissues.
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